P E R S O N A L R E F E R E N C E / 2 0 2 6 E D I T I O N PRESCRIPTION ANCILLARIES A clear, practical reference to the nine medications discussed for bodybuilding-adjacent health management. A T A G L A N C E 9 MEDICATIONS / 7 CATEGORIES GYNECOMASTIA Tamoxifen / Nolvadex 20 mg daily • 6–12 wk studied ESTROGEN MANAGEMENT Exemestane / Aromasin 6.25 mg • twice weekly proposed BLOOD PRESSURE Telmisartan 40–80 mg daily BLOOD PRESSURE Nebivolol 5–10 mg daily LIPIDS Rosuvastatin 5–10 mg daily LIPIDS Ezetimibe 10 mg daily ERECTILE FUNCTION Tadalafil / Cialis 5 mg daily PROLACTIN Cabergoline 0.25 mg proposed GLUCOSE / CARDIORENAL Empagliflozin / Jardiance 10 mg daily • 25 mg if indicated Amounts shown are study regimens, label doses, or personal reference notes. They are not instructions to take these medications together. COMBINATION USE / ONLY WHEN WARRANTED Several of these medications may be prescribed together when each is justified by bloodwork, symptoms and clinical assessment. The complete combination is not automatically safe; a prescriber must review interactions and monitoring. O F F S E A S O N / R X F I E L D G U I D E 02 / 05 HORMONAL MANAGEMENT Gyno & estradiol Two different mechanisms: receptor blockade in breast tissue versus reduced estrogen production. G Y N O F L A R E R E F E R E N C E Tamoxifen / Nolvadex 20 mg daily • 6–12 weeks (studied) A SERM that blocks estrogen signaling in breast tissue without directly lowering E2. May relieve tenderness and reduce recently developed glandular tissue. 2 0 2 6 G U I D E L I N E / I M P O R T A N T D I S T I N C T I O N SIAMS suggests tamoxifen 20 mg/day for 3–6 months in selected recent-onset idiopathic gynecomastia (under 6 months). This expert-opinion guidance is not specific to steroid-induced cases. E S T R A D I O L M A N A G E M E N T Exemestane / Aromasin 6.25 mg • twice weekly (proposed) An irreversible aromatase inhibitor that reduces the synthesis of estrogen. Check baseline sensitive E2 (LC-MS/MS); recheck after a consistent regimen. Repeat after dose changes; continue periodic testing even without symptoms. W H Y A R O M A S I N I S D I F F E R E N T ACTIVE AROMATASE EXEMESTANE BINDS ENZYME INACTIVATED Exemestane permanently inactivates each enzyme it binds ("suicide inhibition"). If E2 becomes too low, those enzymes do not reactivate when the drug clears; estrogen production recovers as the body makes new aromatase enzymes. The effect is therefore not permanent, but recovery is not instant. EDUCATIONAL REFERENCE / NOT A COMBINED PRESCRIPTION 02 O F F S E A S O N / R X F I E L D G U I D E 03 / 05 CARDIOVASCULAR MANAGEMENT Blood pressure & lipids Two complementary blood-pressure options and two complementary LDL-lowering mechanisms. B L O O D P R E S S U R E Telmisartan 40–80 mg daily ARB that blocks angiotensin II signaling to help blood vessels relax. Treats confirmed hypertension. Relevant when increased body mass or fluid retention raises blood pressure. Long duration supports once-daily control. B L O O D P R E S S U R E Nebivolol / Bystolic 5–10 mg daily Beta-1 blocker with nitric-oxide-mediated vasodilating effects. Reduces blood pressure and resting heart rate. May help when tachycardia is part of a clinically evaluated problem. Usual starting dose: 5 mg daily. C H O L E S T E R O L Rosuvastatin / Crestor 5–10 mg daily Statin that reduces cholesterol production in the liver. Lowers LDL-C and ApoB-containing particles. Useful when lab-confirmed lipids and overall risk indicate treatment. Dose is informed by lipid results. C H O L E S T E R O L Ezetimibe / Zetia 10 mg daily Reduces cholesterol absorption through the intestine. Lowers LDL-C and ApoB via a different pathway than statins. Can add LDL reduction alongside rosuvastatin. B O D Y B U I L D I N G C O N T E X T Higher bodyweight, androgen exposure, and fluid changes can alter blood pressure and lipid markers. The useful approach is to match treatment to measured blood pressure and lipid results, rather than assume all medications are necessary. Useful measures: home BP and pulse; LDL-C and ApoB bloodwork. EDUCATIONAL REFERENCE / NOT A COMBINED PRESCRIPTION 03 O F F S E A S O N / R X F I E L D G U I D E 04 / 05 FUNCTION & METABOLIC HEALTH Three additional roles Erectile function, confirmed prolactin disorders, and glucose-related treatment. E R E C T I L E F U N C T I O N Tadalafil / Cialis 5 mg daily PDE5 inhibitor that supports erectile blood flow through nitric oxide–cGMP signaling. Daily dosing gives a sustained therapeutic effect; may modestly lower BP. Bodybuilders sometimes describe better pumps, but increased muscle growth has not been established. P R O L A C T I N M A N A G E M E N T Cabergoline 0.25 mg (proposed amount) Dopamine D2 agonist that suppresses pituitary prolactin secretion. Used for confirmed hyperprolactinemia, not routine nandrolone use. May improve sexual symptoms when high prolactin is the actual cause. Usually prescribed on a scheduled, lab-guided basis rather than as needed. G L U C O S E & C A R D I O R E N A L Empagliflozin / Jardiance 10 mg daily • 25 mg if indicated SGLT2 inhibitor: lowers blood glucose by increasing glucose loss through urine, independently of insulin. May be relevant to clinically elevated glucose during HGH use, but does not directly reverse insulin resistance. Has established heart/kidney benefits in specific diagnosed conditions. 10 mg is the usual starting dose; 25 mg is for additional glucose control when indicated. Use a 10 mg tablet for a 10 mg dose; do not assume a 25 mg tablet splits accurately. EDUCATIONAL REFERENCE / NOT A COMBINED PRESCRIPTION 04 O F F S E A S O N / R X F I E L D G U I D E 05 / 05 MONITORING & SOURCES Keep the numbers useful Short reminders to pair each category with the measurement that actually informs it. M E A S U R E M E N T M A P GYNECOMASTIA Symptoms + clinician examination; evaluate persistent or new lumps ESTRADIOL Sensitive E2 by LC-MS/MS + clinical context; repeat after changes BLOOD PRESSURE Repeated seated blood pressure and pulse readings LIPID MANAGEMENT Lipid panel + LDL-C / ApoB + overall cardiovascular risk PROLACTIN Prolactin testing when clinically indicated; consider cause GLUCOSE / SGLT2 Glucose or A1c; kidney function and treatment indication R E A D T H I S B E F O R E U S I N G T H E L I S T The entries combine user-selected reference amounts, published treatment regimens, and approved-label dosing. They are not a recommended stack and should not be treated as interchangeable dosing instructions. Medication decisions should be based on a clinical indication, individual lab results, other prescriptions, and a qualified prescriber. “Use at your own risk” is an acknowledgment of uncertainty, not a substitute for medical evaluation. The anabolic-steroid context does not establish a need for any of these prescriptions. S E L E C T E D R E F E R E N C E S 01 2026 SIAMS gynecomastia clinical guideline doi.org/10.1007/s40618-026-02915-2 02 Tamoxifen 20 mg, 6–12-week study (36 men) pubmed.ncbi.nlm.nih.gov/14759718 03 FDA prescribing information: Aromasin (exemestane) accessdata.fda.gov / label 2024 04 DailyMed: Jardiance (empagliflozin) dailymed.nlm.nih.gov / current label 05 DailyMed: Bystolic (nebivolol) dailymed.nlm.nih.gov / prescribing label EDUCATIONAL REFERENCE / NOT A COMBINED PRESCRIPTION 05